Better Health for All

The company's core business, through its subsidiary Canndoc, delivers GMP-certified, pharmaceutical-grade medical cannabis products for various conditions such as neuropathic pain, epilepsy, Parkinson's, and PTSD, providing expert pharmaceutical guidance and personalized patient care.

Canndoc has provided millions of doses to 40,000 patients and has been pioneering pharma-grade medical cannabis for 11 years. The company's products meet global Good Manufacturing Practice (GMP) regulatory requirements, and it has a perfect safety record with no reported adverse events. Canndoc has offered products at subsidized prices since a new regulatory framework raised prices, and its products are prescribed for minor patients suffering from severe uncontrolled Epilepsy, patients on chemotherapy, and terminal patients. However, the company's website states that information is for informative purposes only and should not be considered medical advice, and directs users to review patient information leaflets and a clinical guide. Canndoc's products are prescribed for Post-traumatic stress disorder (PTSD), and clinical trials are initiated to validate the beneficial effect of GMP pharma-grade cannabis on PTSD. The company conducts clinical research programs, including a phase 3 clinical trial on children with autistic spectrum disorder, led by Dr. Orit Stoller and Prof. Mati Berkovitch, collaborating with leading medical and academic research centers. The company's website provides general information but explicitly states it should not be considered medical advice.

Fair Money & Economic Opportunity

InterCure Ltd. is described as a cannabis company that cultivates, processes, and distributes medical cannabis products. The ethical value 'Fair Money & Economic Opportunity' and its associated KPIs are specifically designed to assess companies involved in lending, insuring, moving, or storing money, focusing on financial products and services. As InterCure Ltd. does not operate in the financial services sector, none of the provided KPIs are applicable to its business model. The article mentions the company has an ESG score

but provides no specific data points relevant to financial inclusion or economic opportunity.

Fair Pay & Worker Respect

No specific, concrete data points were found in the provided articles for any of the KPIs related to Fair Pay & Worker Respect. The articles explicitly state the absence of data for metrics such as living wage coverage, CEO-to-median pay ratio, collective bargaining share, safety incident rate, pay equity ratio, worker engagement score, turnover rate, labor violation incidents, insecure contract share, or health insurance coverage.

The available information primarily focused on employee headcount and financial data.

No War, No Weapons

Intercure Ltd. is a medical cannabis company. There is no evidence that the company derives revenue from arms or defense contracts, develops dual-use technologies, or engages in any other defense-related business activities. Parts of its facility in Kibbutz Nir Oz, Southern Israel, have been used by the Israel Defense Forces (IDF), including the IDF's medical corps, since the war declared on October 7, 2023.

The company has received NIS 81 million in compensation advances from Israeli authorities for war-related damages, part of a total submitted claim of NIS 251 million, but this is for damages, not for providing services or products to the military.

Safe & Smart Tech

No information was found in the provided article regarding InterCure Ltd.'s performance on data protection, cybersecurity, or responsible AI practices.

The article focuses on the impact of the Israeli-Palestinian conflict on the company's physical site and operations, rather than its digital security or privacy measures, rendering all KPIs under 'Safe & Smart Tech' as not applicable.

Zero Waste & Sustainable Products

No specific, concrete data points were found in the provided articles to assess Intercure Ltd. against any of the 'Zero Waste & Sustainable Products' KPIs. The articles primarily discuss an acquisition, general environmental impacts of cannabis cultivation, and the potential for synthetic biology, none of which provide measurable evidence for waste diversion, product recyclability, packaging sustainability, or other related metrics for Intercure Ltd.

The mention of pesticide-free cultivation for Better, an acquired company, does not directly map to the waste and circularity KPIs.